Posts by: Joana Carvalho, PhD

Joana Carvalho, PhD

Joana holds a BSc in Biology, a MSc in Evolutionary and Developmental Biology and a PhD in Biomedical Sciences from Universidade de Lisboa, Portugal. Her work has been focused on the impact of non-canonical Wnt signaling in the collective behavior of endothelial cells — cells that made up the lining of blood vessels — found in the umbilical cord of newborns.

October 8, 2020October 8, 2020

Oral Cannabinoids Linked to Higher Mortality Risk in Older COPD Patients, Study Finds

News

Older patients with chronic obstructive pulmonary disease (COPD) taking oral, synthetically-made cannabinoids — medications based on compounds found naturally in marijuana (the plant Cannabis sativa) — to manage some ... Read more

September 29, 2020September 29, 2020

Two Phase 3 Trials of Ensifentrine in Safely Treating COPD to Open

News

Verona Pharma has launched two Phase 3 trials to assess the safety and effectiveness of ensifentrine, its investigational inhalation treatment for chronic obstructive pulmonary disease (COPD). The trials — ... Read more

September 24, 2020September 24, 2020

COPD More Prevalent Than Estimated, With Mortality Linked to Aspergillosis, Review Finds

News

Chronic obstructive pulmonary disease (COPD) is more prevalent than previously thought and associated with a mortality rate that is likely higher than earlier estimates, a review study has found. ... Read more

August 13, 2020August 13, 2020

PR1P Peptide Reduces Lung Cell Death, Tissue Damage in Emphysema, Preclinical Study Shows

News

PR1P, a small peptide able to increase the activity of vascular endothelial growth factor (VEGF) in cells lining the inside of blood vessels, can reduce lung cell death and ... Read more

June 30, 2020June 30, 2020

Breztri Aerosphere Leads to Lower COPD Exacerbation Rate Compared With Dual Therapies, Trial Shows

News

Breztri Aerosphere, AstraZeneca’s triple combination therapy for chronic obstructive pulmonary disease (COPD), significantly reduces the frequency of moderate or severe exacerbations, compared to dual combination therapies, in patients with ... Read more

June 4, 2020June 4, 2020

Stem Cell Therapy Benefits Patients with Severe Inflammation, Trial Data Show

News

Remestemcel-L, Mesoblast’s lead candidate stem cell therapy for inflammatory diseases, improves lung function and exercise capacity in people with chronic obstructive pulmonary disease (COPD) and a high degree of inflammation, ... Read more

May 21, 2020May 21, 2020

COPD Seen to Raise Risk of Lung Cancer in Non-smokers

News

Chronic obstructive pulmonary disease (COPD) is linked to a higher risk of lung cancer in people who never smoked. In fact, their risk is equivalent to current or former ... Read more

October 29, 2019October 29, 2019

Duaklir Now Available to COPD Patients in US, Circassia Announces

News

Duaklir (aclidinium bromide and formoterol fumarate), a long-term maintenance treatment for chronic obstructive pulmonary disease (COPD), is available to patients living in the U.S., Circassia Pharmaceuticals announced. According to ... Read more

October 25, 2019October 25, 2019

Tudorza Reduces COPD Flare-ups Without Increasing Risk of Cardiovascular Complications or Death, Phase 4 Trial Shows

News

Tudorza (aclidinium bromide) reduces flare-ups in patients with moderate to severe chronic obstructive pulmonary disease (COPD) without increasing the risk of cardiovascular complications such as heart attack and stroke, ... Read more

September 24, 2019September 24, 2019

Vaping Triggers Cellular Responses Similar to Cigarette Smoking, Potentially Increasing Risk of Emphysema

News

The use of electronic cigarettes, more commonly known as vaping, triggers cellular responses in the lungs similar to those elicited by smoking tobacco cigarettes, which may place e-cigarette users ... Read more

Pin It on Pinterest